Frank McCormick, Director at BridgeBio Pharma, Inc. (BBIO), sold 388,120 shares at $65.48 ($25.8M) on 2025-10-29, disclosed to the SEC on 2025-10-31.
Scheduled sale ($25.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.48 | 111,755 | $7.3M | 28.3% |
| 2 | $65.48 | 111,755 | $7.3M | 28.3% |
| 3 | $66.20 | 31,116 | $2.1M | 8.0% |
| 4 | $66.20 | 31,116 | $2.1M | 8.0% |
| 5 | $67.52 | 3,497 | $236K | 0.9% |
| 6 | $67.52 | 3,497 |
| $236K |
| 0.9% |
| 7 | $68.50 | 8,598 | $589K | 2.3% |
| 8 | $69.24 | 43,393 | $3.0M | 11.6% |
| 9 | $69.24 | 43,393 | $3.0M | 11.6% |
| Total | $66.54 avg | 388,120 | $25.8M | 100% |
| Filing → |
| BBIO | SELL | 2025-06-26 | $4.4M | — | Filing → |
| BBIO | SELL | 2023-12-28 | $4.2M | — | Filing → |
| BBIO | SELL | 2020-11-17 | $8.6M | — | Filing → |